Urologic Imaging

How Should You Image for Pretreatment Staging of Upper Tract Urothelial Cancer?

·
How Should You Image for Pretreatment Staging of Upper Tract Urothelial Cancer?

A 68-year-old patient with a long smoking history presents with gross hematuria. A cystoscopy is unrevealing, but a subsequent CT urogram shows a suspicious filling defect in the right renal pelvis. Ureteroscopy with biopsy confirms high-grade urothelial carcinoma. You now face the critical next step: comprehensive pretreatment staging. The goal is to define the local extent of the tumor and, crucially, to rule out regional and distant metastatic disease before committing the patient to a major surgical or systemic treatment pathway. This decision requires a precise imaging strategy. According to the American College of Radiology (ACR) Appropriateness Criteria, several studies are considered best practice, including not only detailed imaging of the abdomen and pelvis but also evaluation of the chest, for which a Radiography chest is rated Usually Appropriate.

Who Fits This Clinical Scenario for Upper Tract Urothelial Cancer Staging?

This guidance applies specifically to adult patients with a new diagnosis of upper urinary tract urothelial cancer (UTUC), which includes tumors arising from the urothelial lining of the renal pelvis or ureter. The patient should be at the pretreatment stage, meaning definitive therapy such as surgery or systemic chemotherapy has not yet been initiated. This workflow is intended for the initial, comprehensive staging that informs the first major treatment decision.

It is critical to distinguish this scenario from related but distinct clinical presentations that require different imaging approaches:

  • Urothelial Cancer of the Bladder: This guidance does not apply to patients whose cancer is known to be confined to the urinary bladder. Both nonmuscle-invasive and muscle-invasive bladder cancers have their own specific staging algorithms, which differ significantly from the workup for UTUC.
  • Post-Treatment Surveillance: This workflow is not for patients who have already undergone treatment for UTUC and are now being monitored for recurrence. Surveillance imaging protocols are different and are guided by the patient’s risk profile and prior treatment.
  • Indeterminate Upper Tract Lesions: While the workup for a suspicious filling defect often leads to this point, this article assumes a tissue diagnosis has been made or is virtually certain. The primary diagnostic phase is complete, and the focus has shifted to staging.

What Diagnoses Are You Working Up in This Scenario?

Pretreatment staging is not about discovering the primary diagnosis—that is already known. Instead, it is a systematic search to determine the anatomic extent of the cancer, which is codified by the Tumor, Node, Metastasis (TNM) staging system. The imaging workup is designed to answer three distinct questions.

Local Tumor Extent (T-stage): The primary goal is to evaluate the depth of tumor invasion. Is the cancer confined to the urothelial lining (noninvasive, Ta, Tis) or has it invaded into the connective tissue or muscle wall (T1-T2)? Crucially, has it extended through the wall into the surrounding fat (peripelvic or periureteric) or invaded adjacent organs like the kidney parenchyma or psoas muscle (T3-T4)? This distinction is a primary determinant of prognosis and treatment strategy.

Regional Lymph Node Involvement (N-stage): The next objective is to assess for spread to regional lymph nodes. For the kidney and proximal ureter, these include the renal hilar, paracaval, and para-aortic nodes. For the distal ureter, pelvic lymph nodes are at risk. The presence of nodal metastases (N1-N3) significantly worsens prognosis and often prompts consideration of neoadjuvant (pre-surgical) chemotherapy.

Distant Metastases (M-stage): Finally, imaging must survey the most common sites of distant spread for UTUC. The most frequent location for distant metastases is the lungs, followed by the liver, bone, and non-regional lymph nodes. Identifying distant disease (M1) fundamentally changes the treatment goal from curative-intent local therapy to systemic treatment aimed at controlling widespread disease.

Why Are CT Urography and Chest Imaging Usually Appropriate for Staging UTUC?

A comprehensive staging evaluation for UTUC requires a multi-part imaging approach to accurately assess the T, N, and M stages. The ACR designates several modalities as Usually Appropriate, reflecting the need to visualize both the urinary tract in detail and screen for distant disease.

The cornerstone for evaluating local and regional disease is multiphase cross-sectional imaging of the abdomen and pelvis.

  • CTU without and with IV contrast is the workhorse modality for most patients. Its multiphase protocol is purpose-built for this task. The non-contrast phase identifies calcifications or stones. The corticomedullary and nephrographic phases assess the renal parenchyma and enhancement of the primary tumor. Critically, the delayed excretory phase opacifies the entire collecting system, ureters, and bladder, providing a detailed “road map” essential for detecting the primary tumor, assessing its size, and identifying any synchronous tumors elsewhere in the urothelium. This modality carries a radiation dose of ☢☢☢☢ 10-30 mSv.
  • MRU without and with IV contrast is an excellent non-radiation alternative, also rated Usually Appropriate. It is particularly valuable for patients with contraindications to iodinated contrast media or in younger patients where radiation dose is a concern. MRU can offer superior soft-tissue contrast, which may aid in assessing the depth of tumor invasion (T-staging). The radiation dose is O 0 mSv.

For evaluating distant metastatic disease (M-stage), chest imaging is essential.

  • Radiography chest is rated Usually Appropriate and serves as a fast, low-cost, and very low-dose (☢ <0.1 mSv) screening tool for pulmonary metastases. In a patient with a seemingly small, low-grade tumor, a negative chest radiograph may be sufficient for the initial M-staging.
  • CT chest with IV contrast is also Usually Appropriate and provides much higher sensitivity for detecting small lung nodules. It is often the preferred modality for patients with high-risk features (e.g., high-grade tumor, hydronephrosis, large tumor size) and can be performed during the same session as the CTU, providing a complete staging workup in a single appointment. Its radiation dose is ☢☢☢ 1-10 mSv.

In contrast, some common imaging studies are considered Usually not appropriate for this specific staging scenario. For example, US kidneys and bladder retroperitoneal lacks the spatial resolution and functional information to accurately determine the T-stage or evaluate lymph nodes. Similarly, a routine Bone scan whole body is not recommended for asymptomatic patients, as bone metastases are uncommon in the absence of advanced disease or specific symptoms like bone pain.

What’s Next After Staging? Interpreting Results and Planning Treatment

The results of the staging examinations directly guide the downstream clinical workflow and are best discussed in a multidisciplinary tumor board.

  • Organ-Confined Disease (e.g., ≤T2, N0, M0): If imaging demonstrates the tumor is confined to the renal pelvis or ureter without evidence of nodal or distant spread, the patient is typically a candidate for curative-intent surgery. The standard of care is a radical nephroureterectomy (RNU), which involves removal of the kidney, ureter, and a small cuff of the bladder. Imaging is critical for planning the surgical approach (open, laparoscopic, or robotic).
  • Locally Advanced Disease (e.g., T3/T4 or N+): When imaging suggests the tumor has extended beyond the muscular wall or involves regional lymph nodes, neoadjuvant (preoperative) systemic chemotherapy is often recommended. This approach aims to shrink the tumor, treat micrometastatic disease, and improve surgical outcomes. The imaging findings are the primary trigger for this treatment pathway.
  • Metastatic Disease (M1): If the chest or abdominal imaging reveals distant metastases in the lungs, liver, bones, or elsewhere, the treatment intent shifts from local cure to systemic control. The primary treatment becomes platinum-based chemotherapy or immunotherapy. Surgery may still play a role in palliating symptoms like bleeding or obstruction but is no longer the primary curative modality.
  • Indeterminate Findings: An indeterminate 1 cm lymph node or a 5 mm lung nodule presents a clinical challenge. Such findings may prompt further investigation with FDG-PET/CT skull base to mid-thigh (rated May be appropriate) for problem-solving or a plan for short-term follow-up imaging after initiation of treatment.

Common Pitfalls in Staging Upper Tract Urothelial Cancer

Accurate staging is paramount, and several common errors can compromise the quality of the workup. First, ordering a standard “CT Abdomen/Pelvis with contrast” instead of a dedicated CT Urography (CTU) is a frequent mistake; without the delayed excretory phase, small or flat urothelial lesions can be easily missed. Second, co-existing inflammation or infection from tumor-induced obstruction can mimic soft-tissue invasion, potentially leading to overstaging; correlating with clinical signs of infection is essential. Finally, it’s crucial to scrutinize the entire urothelial tract on imaging, including the contralateral kidney/ureter and the bladder, as synchronous tumors occur in a meaningful number of patients and will alter the surgical plan.

If staging results are ambiguous, particularly regarding lymph node status or resectability, the case should be escalated for review at a multidisciplinary genitourinary tumor board.

Related ACR Topics and Tools

For a comprehensive overview of imaging for all clinical variants of urothelial cancer, please see our parent guide. For additional tools to help refine your imaging orders, explore the resources below.

Frequently Asked Questions

Why is CT Urography preferred over a standard CT Abdomen/Pelvis for UTUC?

A standard CT Abdomen/Pelvis is optimized for evaluating solid organs like the liver and kidneys in an arterial or portal venous phase. A CT Urography (CTU) is a specialized protocol that adds a non-contrast phase to detect stones and, most importantly, a delayed excretory phase. This final phase fills the renal collecting systems, ureters, and bladder with contrast, which is essential for outlining tumors within the urothelium that would otherwise be invisible.

My patient has poor renal function. How can I stage their UTUC?

MR Urography (MRU) without and with IV contrast is rated ‘Usually Appropriate’ by the ACR and is an excellent radiation-free alternative. It is often the modality of choice for patients with impaired renal function or a severe allergy to iodinated contrast. If gadolinium-based contrast agents are also contraindicated, a combination of non-contrast MRI, retrograde pyelography, and non-contrast CT can be used, though it may be less comprehensive than a single cross-sectional study.

Is a PET/CT scan necessary for the initial staging of all UTUC patients?

No. According to the ACR, FDG-PET/CT is rated ‘May be appropriate’ and is not recommended for routine initial staging. Its primary role is as a problem-solving tool for clarifying equivocal findings on CT or MRI, such as borderline-sized lymph nodes or suspected metastases, or in the workup of a patient with metastatic urothelial cancer from an unknown primary site.

Should I order a chest radiograph or a chest CT for metastatic screening?

Both are rated ‘Usually Appropriate.’ A chest radiograph is a very low-dose, effective initial screening tool. A chest CT is more sensitive for detecting small metastatic nodules and is often preferred for patients with high-risk disease (e.g., high-grade tumor, large size, hydronephrosis). The choice often depends on institutional protocols and the patient’s specific risk profile. For high-risk patients, a chest CT is often performed at the same time as the CTU for efficiency.

What if the patient has a synchronous tumor in the bladder?

This is a known risk, as the entire urothelium is susceptible. The staging workup must fully characterize both the upper tract and bladder lesions. The bladder tumor would be staged according to its own specific criteria (e.g., nonmuscle-invasive vs. muscle-invasive), which follows a different ACR workflow. The comprehensive treatment plan must then be designed to address both cancer sites appropriately.

Reviewed by Pouyan Golshani, MD, Interventional Radiologist — May 30, 2026